{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["100(5)"],"submitter":["Isogai T"],"pubmed_abstract":["Background
The cerebral embolic protection (CEP) device captures embolic debris during transcatheter aortic valve replacement (TAVR). However, the impact of CEP on stroke severity following TAVR remains unclear. Therefore, we aimed to examine whether CEP was associated with reduced severity of stroke following TAVR.Methods
This was a retrospective cohort study of 2839 consecutive patients (mean age: 79.2 ± 9.5 years, females: 41.5%) who underwent transfemoral TAVR at our institution between 2013 and 2020. We categorized patients into Sentinel CEP users and nonusers. Neuroimaging data were reviewed and the final diagnosis of a cerebrovascular event was adjudicated by a neurologist blinded to the CEP use or nonuse. We compared the incidence and severity (assessed by the Natio"],"journal":["Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions"],"pagination":["810-820"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9805232"],"repository":["biostudies-literature"],"pubmed_title":["Cerebral embolic protection and severity of stroke following transcatheter aortic valve replacement."],"pmcid":["PMC9805232"],"pubmed_authors":["Kapadia SR","Krishnaswamy A","Puri R","Spilias N","Saad AM","Reed GW","Shekhar S","Yun JJ","Agrawal A","Popovic ZB","Unai S","Vanguru HR","Verma BR","Isogai T","Uchino K"],"additional_accession":[]},"is_claimable":false,"name":"Cerebral embolic protection and severity of stroke following transcatheter aortic valve replacement.","description":"Background
The cerebral embolic protection (CEP) device captures embolic debris during transcatheter aortic valve replacement (TAVR). However, the impact of CEP on stroke severity following TAVR remains unclear. Therefore, we aimed to examine whether CEP was associated with reduced severity of stroke following TAVR.Methods
This was a retrospective cohort study of 2839 consecutive patients (mean age: 79.2 ± 9.5 years, females: 41.5%) who underwent transfemoral TAVR at our institution between 2013 and 2020. We categorized patients into Sentinel CEP users and nonusers. Neuroimaging data were reviewed and the final diagnosis of a cerebrovascular event was adjudicated by a neurologist blinded to the CEP use or nonuse. We compared the incidence and severity (assessed by the Natio","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-27T22:31:24.417Z","creation":"2025-02-19T02:38:02.896Z"},"accession":"S-EPMC9805232","cross_references":{"pubmed":["35916117"],"doi":["10.1002/ccd.30340"]}}